Search Results - "Doecke, J. D."

A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study by Burnham, S C, Faux, N G, Wilson, W, Laws, S M, Ames, D, Bedo, J, Bush, A I, Doecke, J D, Ellis, K A, Head, R, Jones, G, Kiiveri, H, Martins, R N, Rembach, A, Rowe, C C, Salvado, O, Macaulay, S L, Masters, C L, Villemagne, V L

“…Dementia is a global epidemic with Alzheimer’s disease (AD) being the leading cause. Early identification of patients at risk of developing AD is now becoming…”
Get full text

Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? by Neale, R E, Doecke, J D, Pandeya, N, Sadhegi, S, Green, A C, Webb, P M, Whiteman, D C

“…Since hyperinsulinaemia may promote obesity-linked cancers, we compared type 2 diabetes prevalence among oesophageal adenocarcinoma (OAC) patients and…”
Get full text

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment by Cheng, L, Doecke, J D, Sharples, R A, Villemagne, V L, Fowler, C J, Rembach, A, Martins, R N, Rowe, C C, Macaulay, S L, Masters, C L, Hill, A F

“…There is no consensus for a blood-based test for the early diagnosis of Alzheimer’s disease (AD). Expression profiling of small non-coding RNA’s, microRNA…”
Get full text

Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease by Simms, L A, Doecke, J D, Walsh, M D, Huang, N, Fowler, E V, Radford-Smith, G L

“…Reduced ileal Paneth cell alpha-defensin expression has been reported to be associated with Crohn's disease, especially in patients carrying NOD2 mutations…”
Get more information

Editorial: first among Equals—not for either infliximab or adalimumab in Crohn's disease—yet by Lim, M. H., Doecke, J. D., Radford‐Smith, G. L.

“…Linked Content This article is linked to Singh et al paper. To view this article visit https://doi.org/10.1111/apt.14466…”
Get full text

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study by Doecke, J. D., Hartnell, F., Bampton, P., Bell, S., Mahy, G., Grover, Z., Lewindon, P., Jones, L. V., Sewell, K., Krishnaprasad, K., Prosser, R., Marr, D., Fischer, J., R Thomas, G., Tehan, J. V., Ding, N. S., Cooke, S. E., Moss, K., Sechi, A., De Cruz, P., Grafton, R., Connor, S. J., Lawrance, I. C., Gearry, R. B., Andrews, J. M., Radford‐Smith, G. L.

“…Summary Background Maintenance anti‐tumour necrosis factor‐α (anti‐TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate…”
Get full text

Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors’ reply by Radford‐Smith, G. L., Hartnell, F., Doecke, J. D.

“…Linked ContentThis article is linked to Doecke and Hartnell et al and Barreiro‐de Acosta and Gisbert papers. To view these articles visit…”
Get full text

Seasonal bone mass of college and senior female field hockey players by BECK, B. R, DOECKE, J. D

“…The purpose of the study was to observe the relationship of field hockey playing with bone, muscle and fat in young and older adult women. We measured body…”
Get full text

A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease by Piccirella, Simona, Van Neste, L., Fowler, C., Masters, C. L., Fripp, J., Doecke, J. D., Xiong, C., Uberti, D., Kinnon, P.

“…Background Ongoing research seeks to identify blood-based biomarkers able to predict onset and progression of Alzheimer’s disease (AD). Objective The unfolded…”
Get full text

Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum by Feizpour, A., Doré, V., Doecke, J. D., Saad, Z. S., Triana-Baltzer, G., Slemmon, R., Maruff, P., Krishnadas, N., Bourgeat, P., Huang, K., Fowler, C., Rainey-Smith, S. R., Bush, A. I., Ward, L., Robertson, J., Martins, R. N., Masters, C. L., Villemagne, V. L., Fripp, J., Kolb, H. C., Rowe, Christopher C.

“…Background Plasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β (Aβ) and tau…”
Get full text

Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? by Neale, R E, Doecke, J D, Pandeya, N, Sadeghi, S, Green, A C, Webb, P M, Whiteman, D C

Get full text

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid by Lifke, Valeria, Kollmorgen, Gwendlyn, Manuilova, Ekaterina, Oelschlaegel, Tobias, Hillringhaus, Lars, Widmann, Monika, von Arnim, Christine A.F., Otto, Markus, Christenson, Robert H., Powers, Jennifer L., Shaw, Leslie M., Hansson, Oskar, Doecke, James D., Li, Qiao-Xin, Teunissen, Charlotte, Tumani, Hayrettin, Blennow, Kaj

“…Total tau (tTau) and phosphorylated 181P tau (pTau) are supportive diagnostic cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease. Manual CSF tau…”
Get full text

Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS by Shaw, Leslie M., Hansson, Oskar, Manuilova, Ekaterina, Masters, Colin L., Doecke, James D., Li, Qiao-Xin, Rutz, Sandra, Widmann, Monika, Leinenbach, Andreas, Blennow, Kaj

“…Alzheimer's disease (AD) biomarkers, such as cerebrospinal fluid (CSF) amyloid-β (1–42; Aβ42), can provide high diagnostic accuracy. Several immunoassays are…”
Get full text

A blood-based predictor for neocortical A[beta] burden in Alzheimer's disease: results from the AIBL study by Burnham, S C, Faux, N G, Wilson, W, Laws, S M, Ames, D, Bedo, J, Bush, A I, Doecke, J D, Ellis, K A, Head, R, Jones, G, Kiiveri, H, Martins, R N, Rembach, A, Rowe, C C, Salvado, O, Macaulay, S L, Masters, C L, Villemagne, V L

“…Dementia is a global epidemic with Alzheimer's disease (AD) being the leading cause. Early identification of patients at risk of developing AD is now becoming…”
Get full text

Erratum: Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? by Neale, R E, Doecke, J D, Pandeya, N, Sadeghi, S, Green, A C, Webb, P M, Whiteman, D C

“…Correction to: British Journal of Cancer (2009) 100, 795–798. doi:10.1038/sj.bjc.6604908 During submission of the above article to the journal, one of the…”
Get full text

Association of Functionally Different RUNX2 P2 Promoter Alleles With BMD by Doecke, James D, Day, Christopher J, Stephens, Alexandre SJ, Carter, Shea L, van Daal, Angela, Kotowicz, Mark A, Nicholson, Geoff C, Morrison, Nigel A

“…RUNX2 gene SNPs were genotyped in subjects from the upper and lower deciles of age‐ and weight‐adjusted femoral neck BMD. Of 16 SNPs in RUNX2 and its two…”
Get full text